Claire Cassedy's blogs

KEI Comments filed in USTR Special 301 Review

On February 9, 2017, KEI filed written comments to the Office of the United States Trade Representative’s Special 301 Review process.

The Special 301 Review is an annual process carried out by the USTR to, “to identify countries that deny adequate and effective protection of intellectual property rights (IPR) or deny fair and equitable market access to U.S. persons who rely on intellectual property protection.”

Add new comment Read more

Feb 24, 2017 – U.S. History, Experiences, and Prospects of Compulsory Licensing of Medical Patents


On Friday, February 24, 2017, KEI hosted a meeting exploring compulsory licensing in the United States.

Title: History, Experiences, and Prospects of Compulsory Licensing on Medical Patents in the United States
Date: Friday February 24, 2017
Location: Kaiser Permanente Center for Total Health
700 Second St. NE (near Union Station)
Washington, DC 20002

Add new comment Read more

2016: Kite Pharma, KEI Comments on NIH Proposed Exclusive License for Cancer Treatment

Today, KEI submitted comments to the Notice published in the Federal Register on October 5, 2016, entitled “Prospective Grant of Exclusive Patent License: Development of Anti-CD70 Chimeric Antigen Receptors for the Treatment of CD70 Expressing Cancers.” KEI’s comments addressed issues with the NIH’s processes for granting exclusive licenses, and transparency in those licenses, resulting data, trials, pricing, and revenue.

Add new comment Read more

Commentary on Hillary Clinton’s Plan to Respond to Unjustified Price Hikes for Long-Available Drugs

Democratic presidential nominee Hillary Clinton has published a factsheet presenting, “Hillary’s Plan to Respond to Unjustified Price Hikes for Long-Available Drugs.”

Today via Twitter, KEI Director James Love offered a six point commentary on Secretary Clinton’s proposal to address drug price hikes:

Add new comment Read more

Two page summary: What does the TPP do as regards prices of drugs and other medical technologies?

Attached is a 2 page summary of the main provisions in the Trans-Pacific Partnership Agreement (TPP) that will lead to higher prices for drugs and other medical technologies.

A pdf version of the note is available here: /wp-content/uploads/KEI-TPP-Briefing-2015-2-A2M.pdf


What does the TPP do as regards prices of drugs and other medical technologies?

KEI TPP Briefing note 2015:2
June 10, 2015

Add new comment Read more

Sign-on Letter to USTR, be honest about impact of TPP on prices, access to medicines

KEI is circulating a sign on letter to be sent to Ambassador Michael Froman of USTR. We learned that in a USTR has been stating that there was no evidence that stronger intellectual property rules created barriers for access to medicine.

This is a shocking statement for USTR to make, and we are seeking confirmation and clarification of USTR’s assertion. The text of our letter follows below.

If you would like to sign on to this letter, please send your name, city and state of residence, and affiliation if any, along with contact details (only for confirmation if necessary), to:

Add new comment Read more